Zepbound FDA Approval History: Timeline, Label, and Safety Record

What Is Zepbound and How Did It Reach the FDA?

Zepbound is the branded weight-management formulation of tirzepatide, a synthetic peptide that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. Eli Lilly had already obtained FDA approval for tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022. The Zepbound NDA (NDA 217806) was a separate submission targeting chronic weight management, supported primarily by the SURMOUNT clinical program.

The Dual-Receptor Mechanism Behind the Filing

GLP-1 receptor agonists were already an established class when Lilly began its weight-management program. Tirzepatide's GIP component adds a complementary mechanism: GIP receptors are expressed in adipose tissue and may amplify fat oxidation and reduce the GI side effects seen with pure GLP-1 agonists. The FDA reviewed this pharmacology as part of the NDA's clinical pharmacology section. Preclinical data showed dose-dependent weight loss in rodent models, and early phase 1 data in healthy volunteers confirmed subcutaneous bioavailability exceeding 80%, supporting the once-weekly dosing regimen eventually approved.

From Mounjaro Data to a New NDA

Because tirzepatide's metabolic effects in Mounjaro trials were striking, Lilly ran a dedicated obesity program rather than seeking a labeling expansion. This is clinically significant: Zepbound carries a distinct indication, a distinct titration schedule optimized for weight loss rather than glycemic control, and a product label that explicitly addresses patients without type 2 diabetes. The FDA's Office of New Drugs, Division of Diabetes, Lipid Disorders, and Obesity handled the review.

The November 8, 2023 Approval: Chronic Weight Management

On November 8, 2023, the FDA approved Zepbound as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. FDA approval letter, NDA 217806

Key Evidence: SURMOUNT-1

The primary key trial was SURMOUNT-1, published in the New England Journal of Medicine in 2022. The trial enrolled 2,539 adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity but without type 2 diabetes. Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks.

At 72 weeks, mean body-weight reductions were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% in the placebo group (P<0.001 for all comparisons). [1] The proportion of participants achieving at least 5% weight loss was 85% in the 15 mg group versus 35% in the placebo group. These effect sizes exceeded those previously seen with semaglutide 2.4 mg (Wegovy), which produced a mean 14.9% weight loss at 68 weeks in STEP-1 (N=1,961). [2]

The SURMOUNT-1 authors concluded: "Treatment with tirzepatide resulted in substantial and sustained reductions in body weight." [1]

SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4

The FDA's review package included data from three additional SURMOUNT trials:

• SURMOUNT-2 enrolled 938 adults with type 2 diabetes and obesity; tirzepatide 15 mg produced 14.7% mean weight loss versus 3.2% placebo at 72 weeks. [3]
• SURMOUNT-3 tested a 12-week intensive lifestyle intervention lead-in before randomization; participants on tirzepatide 15 mg lost an additional 18.4% from the post-lead-in baseline. [4]
• SURMOUNT-4 evaluated weight regain after tirzepatide withdrawal; participants rerandomized to placebo regained 14% of body weight over 52 weeks, supporting the drug's label language about long-term use. [5]

The combined dataset across SURMOUNT-1 through SURMOUNT-4 formed what the FDA described in its medical review as a "strong efficacy package" supporting a broad weight-management indication rather than a disease-specific one.

The June 21, 2024 Approval: Obstructive Sleep Apnea

On June 21, 2024, the FDA approved a second indication for Zepbound: treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, used with or without positive airway pressure (PAP) therapy. FDA press release, June 21, 2024

This made Zepbound the first and, as of mid-2025, only drug approved specifically for OSA in the United States.

Key Evidence: SURMOUNT-OSA

The OSA indication was supported by two replicate phase 3 trials grouped under SURMOUNT-OSA, published in the New England Journal of Medicine in 2024. Trial 1 enrolled participants not using PAP therapy (N=234); trial 2 enrolled participants on PAP therapy (N=235). Both trials ran 52 weeks with tirzepatide titrated to a maximum of 15 mg weekly.

In trial 1, tirzepatide reduced the apnea-hypopnea index (AHI) by a mean of 27.4 events per hour versus 4.8 events per hour with placebo (P<0.001). In trial 2, the reduction was 30.4 versus 6.0 events per hour (P<0.001). [6] Body-weight reduction in both trials was approximately 18%, consistent with the broader SURMOUNT dataset.

The FDA's approval letter noted that the OSA benefit was mediated substantially, though not entirely, through weight loss, and the label does not require a minimum weight-loss threshold before the indication applies.

The Zepbound Label: Key Prescribing Details

The current Prescribing Information (PI) for Zepbound, last updated following the OSA approval, covers several sections that clinicians and patients frequently ask about.

Dosing and Titration

Zepbound starts at 2.5 mg subcutaneously once weekly for 4 weeks, then 5 mg once weekly. Dose escalation by 2.5 mg increments every 4 weeks is permitted as tolerated. The maintenance dose range is 5 mg to 15 mg once weekly. No dose adjustment is required for mild or moderate renal impairment or for mild hepatic impairment. Data for severe renal or hepatic impairment are limited, and the label recommends caution in those populations. [7]

Contraindications

The label lists two absolute contraindications:

1. Personal or family history of medullary thyroid carcinoma (MTC).
2. Multiple endocrine neoplasia syndrome type 2 (MEN2).

These contraindications derive from a preclinical finding: tirzepatide caused thyroid C-cell adenomas and carcinomas in rodents at clinically relevant exposures. Human relevance is unknown because human thyroid tissue expresses GLP-1 and GIP receptors at lower density than rodent tissue, but the FDA required the boxed warning as a precautionary measure. [7]

Warnings and Precautions

The label includes warnings for:

• Pancreatitis. Patients should discontinue Zepbound if pancreatitis is suspected. The label does not mandate baseline lipase monitoring but advises clinicians to observe for symptoms.
• Acute gallbladder disease. Rapid weight loss is associated with gallstone formation. SURMOUNT-1 reported cholelithiasis in 1.2% of the 15 mg group versus 0.4% placebo.
• Hypoglycemia with concomitant insulin or sulfonylurea. Dose reduction of the concomitant agent is recommended.
• Acute kidney injury. Secondary to nausea, vomiting, and dehydration; patients on diuretics or ACE inhibitors warrant monitoring.
• Hypersensitivity. Anaphylaxis and angioedema have been reported; Zepbound should not be used in patients with known hypersensitivity to tirzepatide.
• Suicidal ideation. The FDA added a monitoring recommendation for neuropsychiatric events consistent with the class-wide review of GLP-1 receptor agonists conducted in 2023 to 2024.

Pregnancy and Lactation

The label assigns Zepbound to a category where use in pregnancy is not recommended because animal reproduction studies showed embryo-fetal toxicity at doses producing exposures similar to human therapeutic exposures. Females of reproductive potential should use effective contraception because tirzepatide may reduce the efficacy of oral contraceptives for approximately 4 weeks after each dose escalation step.

No data exist on the presence of tirzepatide in human breast milk; the label recommends against use while breastfeeding.

Post-Market Safety: What FDA Surveillance Has Found

FDA Adverse Event Reporting System (FAERS) Signals

Since the November 2023 approval, FAERS has accumulated reports on Zepbound as a distinct product separate from Mounjaro. The most frequently reported adverse events mirror the clinical trial profile: nausea (affecting up to 31.0% of patients in SURMOUNT-1 at 15 mg), diarrhea (22.1%), vomiting (15.0%), and constipation (17.6%). [1] These events are predominantly grade 1 to 2, occur early in the titration period, and resolve in most patients by week 12 to 20.

A signal of aspiration during procedures requiring general anesthesia was identified across the GLP-1 class. The American Society of Anesthesiologists issued guidance in August 2023 recommending that patients withhold GLP-1 and dual-agonist medications for at least one injection cycle before elective procedures under general anesthesia. As of mid-2025, the Zepbound label does not include a formal preoperative hold recommendation, but this is under active FDA review.

Thyroid Monitoring and the Calcitonin Question

Tirzepatide activates GLP-1 receptors on thyroid C cells in rodents, driving calcitonin secretion and, at high cumulative exposures, C-cell tumors. Post-market data from Mounjaro (approved May 2022) have not established a signal for elevated calcitonin or MTC in humans. A 2024 pharmacoepidemiologic study in NEJM Evidence found no excess risk of MTC in GLP-1 agonist users compared with users of other antidiabetic agents over a median 3.9 years of follow-up, though the authors noted that MTC latency may exceed current observation periods. [8]

The label continues to recommend monitoring for symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness) and does not mandate routine calcitonin screening.

Cardiovascular Outcomes: SURMOUNT-MMO

The dedicated cardiovascular outcomes trial for tirzepatide in obesity, SURMOUNT-MMO (NCT05556512), was ongoing as of early 2025. Interim analyses have not been published. The FDA granted the weight-management indication without a completed CVOT because the precedent set by the semaglutide SELECT trial provided a class-level basis for cardiovascular benefit, and the agency required Lilly to submit SURMOUNT-MMO results post-approval.

For comparison, the semaglutide 2.4 mg SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) over a mean 39.8 months in adults with obesity and established cardiovascular disease. [9] No equivalent tirzepatide CVOT data at the weight-management dose are yet available.

Regulatory Milestones: A Chronological Reference

The table below consolidates the key regulatory actions affecting Zepbound from the original NDA submission through mid-2025.

| Date | Regulatory Action | |---|---| | May 2022 | Tirzepatide (Mounjaro) approved for type 2 diabetes (NDA 215866) | | Early 2023 | NDA 217806 (Zepbound) submitted to FDA | | November 8, 2023 | Zepbound approved for chronic weight management (BMI 30+, or 27+ with comorbidity) | | June 21, 2024 | Zepbound approved for moderate-to-severe OSA in adults with obesity | | August 2024 | FDA shortage designation lifted for some Zepbound doses as supply normalized | | Ongoing | SURMOUNT-MMO CVOT continues; FDA reviewing preoperative hold language |

How Zepbound's Approval Compares to Semaglutide 2.4 mg (Wegovy)

Wegovy received FDA approval in June 2021 for chronic weight management using a near-identical indication statement. The regulatory paths share several features:

• Both required a dedicated NDA separate from the diabetes formulation (Ozempic for semaglutide, Mounjaro for tirzepatide).
• Both carry boxed warnings for thyroid C-cell tumors.
• Both required a dedicated CVOT as a post-market commitment; Novo Nordisk fulfilled its obligation with the SELECT trial; Lilly's SURMOUNT-MMO is pending.

The head-to-head SURMOUNT-5 trial comparing tirzepatide directly against semaglutide 2.4 mg in people with obesity is ongoing as of mid-2025, so no FDA-reviewed comparative efficacy data exist yet. Early open-label data in type 2 diabetes (SURPASS-2, N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.3% versus 1.9% for semaglutide 1 mg, though that trial used different doses than the weight-management approvals. [10]

Access, Prescribing Restrictions, and Insurance Coverage

Zepbound is a Schedule-uncontrolled prescription drug. No REMS program is required. Any licensed prescriber with DEA registration who is authorized to prescribe in the relevant state may write for Zepbound. The drug is not approved for patients under 18 years of age; pediatric studies are ongoing under a post-market pediatric study commitment.

Insurance coverage varies considerably. As of 2025, Medicare Part D covers Zepbound for the OSA indication (approved June 2024) because OSA qualifies as a disease treatment rather than weight management alone. Coverage for the weight-management indication under Medicare Part D was prohibited by the Consolidated Appropriations Act provisions restricting weight-loss drug coverage, though legislative proposals to change this have advanced in Congress.

Commercial payers cover Zepbound with varying prior authorization requirements, typically requiring documentation of BMI and at least one qualifying comorbidity consistent with the label.